Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2009-06-02
2010-12-28
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S629000, C514S043000, C514S659000, C514S661000, C514S662000, C514S563000, C514S459000, C536S028700, C549S424000, C560S128000, C562S507000, C564S456000, C564S458000, C564S459000
Reexamination Certificate
active
07858660
ABSTRACT:
Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.
REFERENCES:
patent: 5360817 (1994-11-01), von Izstein et al.
patent: 5866601 (1999-02-01), Lew et al.
patent: 6605302 (2003-08-01), Faour et al.
patent: 2006/0008459 (2006-01-01), Johnson
patent: 2006/0035859 (2006-02-01), Carter et al.
patent: 2006/0247161 (2006-11-01), Planz et al.
patent: 2007/0270443 (2007-11-01), Went et al.
patent: 2008/0161324 (2008-07-01), Johansen et al.
patent: 2008/0227743 (2008-09-01), Nguyen et al.
patent: 0145727 (2001-06-01), None
patent: WO 01/045727 (2002-06-01), None
patent: 2007/057436 (2007-05-01), None
patent: WO 2007/057436 (2007-07-01), None
Aoki, F.Y, et al., Early administration of oral oseltamivir increases the benefits of influenza treatment, J Antimicrob Chemother 2003, 51:123-29.
Burlington, D.B. et al., Anti-influenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium, J Antimicrob Chemother 1983, 11:7-14.
Colgan, R. et al., Antiviral drugs in the immunocompetent host: part II. Treatment of influenza and respiratory syncytial virus infections, Am Fam Physician 2003, 67(4):763-6, 675 (abstract).
De Clercq, E., Antiviral agents active against influenza A viruses, Nature Reviews, Drug Discovery 2006, 5:1015-25.
De Clercq, E., Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections, Verh K Acad Geneeskd Belg 2006, 68(2):121-37 (Abstract).
De Clercq, E. et al., Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention, TRENDS Pharmacol Sci 2007, 28(6):280-5.
De Jong, M.D., Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection, N Engl J Med 2005, 353:2667-72.
Galabov, A.S. et al., Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice, Antiviral Chem Chemother 2006, 17:251-8.
Galagov, G.A. et al., Combined action of ribovirin and rimantadine in experimental myxovirus infection, Experientia 1976, 33:905-6.
Govorkova, E.A. et al., Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells, Antimicrob Agents Chemother 2004, 48(12):4855-63.
Hayden, F.G. et al., Combined interferon-α2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro, Antimicrob Agents Chemother 1984, 25(1):53-7.
Hayden, F.G. et al., Combinations of antiviral agents for treatment of influenza virus infections, J Antimicrob Chemother 1986, 18(b): 177-83.
Hayden, F.G. et al. Enhancement of activity against influenza viruses by combinations of antiviral agents, Antimicrob Agents Chemother 1980, 18(4):536-41.
Hayden, F.G., Combination antiviral therapy for respiratory virus infections, Antiviral Res 1996, 29:45-8.
Hayden, F.G. et al., Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection, Aniviral Ther 1996, 1:51-6.
Ilyushina N.A., et al., Combination chemotherapy, a potent strategy for reduing the emergence of drug-resistant influenza A variants, Antiviral Res 2006, 70:121-31.
Ilyushina, N.A. et al., Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice, Antiviral Ther 2007, 12:363-70.
Ison, M.G., et al., Therapeutic options for the management of influenza, Curr Opin Pharmacol 2001, 1:482-90.
Ison, M.G., et al., Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza, Antiviral Ther 2003, 8(3):183-90.
Leneva, I.A. et al., The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses, Antiviral Res 2000, 48:101-15.
Leophonte P., Antivirals for influenza, Bull Acad Natl Med 2005, 68(2):121-137.
Lipsitch et al., Antiviral resistance and the control of pandemic influenza, PLoS Med 2007, 4(1):e15. doi:10.1371/ journal.pmed.0040015.
Madren, L.K. et al., In vitro inhibitory effects of combinations of anti-influenza agents Antiviral, Chem Chemother 1995, 6(2):109-13.
Masihi, K.N. et al., Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice, J Chemother 2007, 19(3):295-303.
Morrison, D. et al., a randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination, PLoS ONE 2007, 2(12):e1305.
Moscona, A Oseltamivir resistance—disabling our influenza defenses, N Engl J Med 2005, 353:2633-6.
Smee, D.F. et al., Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses, Antiviral Chem Chemother 2006, 17:185-92.
Smee, D.F. et al., Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin, Chemother 2002, 48:88-93.
Snyder, D.Z. et al., The triple combination indinavir-zidovudine-lamivudine is highly synergistic, Antimicrob Agents Chemother 2000, 44(4):1051-8.
Stein, D.S. et al., Oral ribavirin treatment of influenza A and B, Antimicrob Agents Chemother 1987, 8:1285-7.
Tsiodras, S. et al., Role of combination antiviral therapy in pandemic influenza, BMJ 2007, 334:293-4.
Wilson, S.Z. et al., Amantadine and riavirin aerosol treatment of influenza A and B infection in mice, Antimicrob Agents Chemother 1980, 17(4):642-8.
Wong, S.S.Y. et al. Avian Influenza Virus Infections in Humans, Chest 2006, 129:156-68.
Deltenre, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. Sep. 2004;41(3):462-73.
European search report and opinion dated Mar. 31, 2010 for Application No. 8732015.6.
Ilyushina, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. Nov. 2008;52(11):3889-97.
International search report dated Jun. 3, 2008 for PCT Application No. US2008/56678.
Jean, et al. Proteomic profiling of host cellular proteins incorporated by severe acute respiratory syndrome (SARS)—associated coronavirus virions: Insights into emerging virus biology and new therapeutics targets. Abstracts of the 19th International Conference on Antiviral Research (ICAR). Antiviral Res. May 2006;70(1):p. A29-A30, abstract No. 11.
Leophonte, P. Antivirals for influenza. Bull Acad Natl Med. Feb. 2005;189(2):341-55.
Nguyen, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One. Feb. 22, 2010;5(2):e9332.
Nguyen, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother. Oct. 2009;53(10):4115-26.
Programs and Abstracts of the 19th International Conference on Antiviral Research (ICAR). San Juan, Puerto Rico. May 7-11, 2006.
Smee, et al. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother. May 2009;53 (5):2120-8.
Nguyen et al., “Triple Combination of Amantadine, Ribavirin, and Osetamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Straing in Vitro,” PLoS One 5(2):1-12 (2010).
Nguyen et al., “Triple Comination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strain in Vitro,” Antimicrobial Agents and Chemotherapy 53(10): 4115-4126 (2009).
Hoopes et al., “Evaluation of the Contribution of Amantadine, Ribavirin, and Oseltamivir in a Triple Combination Antiviral Drug (TCAD) Regimen to Suppressing the Emergence of Resistance Using a Novel Quantitative Approach,” Poster shown at 23rdICAR Meeting Apr. 25, 2010, http://isar.phrm.cf.ac.uk
ode/69.
Nguyen et al., “Triple Combination Antiviral Drug (TCAD
Burkoth Terry L.
Chapman Rowan
Chernoff David
Fultz Timothy J.
Nguyen Jack
Adamas Pharmaceuticals, Inc.
Olson Eric S
Wilson Sonsini Goodrich & Rosati
LandOfFree
Compositions and kits for treating influenza does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and kits for treating influenza, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and kits for treating influenza will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173856